Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying same
View Patent ↗T cell memory can persist in the absence of antigen. However, some memory cells by default are subject to signals accompanying periodic antigen exposure. OX40 is essential to the extent and persistence of Th2 memory when antigen is re-encountered. In an animal model of allergic asthma, inhibiting OX40/OX40L signaling during the secondary response to inhaled antigen suppressed lung inflammation. Inhibiting OX40 at the time of memory cell reactivation reduced the longevity of memory with further inflammation prevented upon tertiary encounter with antigen.
1. A method of reducing or inhibiting a recall immune response in a mammalian subject comprising administering an amount of an antibody that specifically binds to OX40 ligand (OX40L) sufficient to reduce or inhibit a recall response in the mammalian subject;
wherein said recall response is caused by an antigen; and
wherein said subject has been previously exposed to said antigen.
2. The method of claim 1 , wherein said immune response is mediated at least in part by OX40 or OX40L.
3. The method of claim 1 , wherein the recall response is a secondary, tertiary or subsequent immune response to an antigen.
4. The method of claim 1 , wherein the mammalian subject is a human.
5. The method of claim 1 , wherein the antibody that specifically binds to OX40L is a human or humanized antibody.
6. The method of claim 1 , wherein the mammalian subject does not have asthma.
7. A method of alleviating or ameliorating a symptom associated with or caused by a recall response in a mammalian subject, comprising administering to a mammalian subject an amount of an antibody that specifically binds to OX40L sufficient to alleviate or ameliorate the symptom associated with or caused by a recall response;
wherein said recall response is caused by an antigen; and
wherein said subject has been previously exposed to said antigen.
8. The method of claim 7 , wherein the symptom associated with or caused by a recall response are symptoms associated with an allergic reaction.
9. The method of claim 8 , wherein the symptom associated with an allergic reaction is swelling, enlargement, mucus production, rash, dermatitis, eosinophil infiltration, leukocyte infiltration, lymphocyte infiltration, increased Th2 cytokine production, hyperplasia, inflammatory lesions or necrosis.
10. The method of claim 8 , wherein the allergic reaction is allergic rhinitis, atopic dermatitis or gastro-intestinal allergies.
11. The method of claim 7 , wherein the recall immune response is a secondary, tertiary or subsequent immune response to an antigen.
12. The method of claim 7 , wherein the mammalian subject is a human.
13. The method of claim 7 , wherein the antibody is a human antibody.
14. The method of claim 13 , wherein the human antibody blocks OX40/OX40L interactions.
15. The method of claim 13 , wherein the human antibody is an IgG.
16. The method of claim 13 , wherein the human antibody is a Fab, Fab′, (Fab′) 2 , Fv, Fd, scFv or sdFv.
17. The method of claim 7 , wherein the antibody is a humanized antibody.
18. The method of claim 7 , wherein the humanized antibody blocks OX40/OX40L interactions.
19. The method of claim 17 , wherein the humanized antibody is an IgG.
20. The method of claim 17 , wherein the humanized antibody is a Fab, Fab′, (Fab′) 2 , Fv, Fd, scFv or sdFv.